

Robert Z Orlowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135374/publications.pdf>

Version: 2024-02-01

268
papers

34,064
citations

8159

76
h-index

3815

178
g-index

269
all docs

269
docs citations

269
times ranked

22662
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. <i>New England Journal of Medicine</i> , 2003, 348, 2609-2617.	13.9	2,460
2	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
3	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
4	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	13.9	1,210
5	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
6	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	0.6	849
7	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1551-1560.	6.3	724
8	Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2002, 20, 4420-4427.	0.8	723
9	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	5.1	723
10	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
11	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 519-527.	6.3	684
12	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
13	Proteasome inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 417-433.	12.5	675
14	Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. <i>Blood</i> , 2007, 110, 3281-3290.	0.6	669
15	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
16	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2012, 120, 2817-2825.	0.6	608
17	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. <i>Journal of Clinical Oncology</i> , 2007, 25, 3892-3901.	0.8	607
18	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, 3113-3120.	0.8	587

#	ARTICLE	IF	CITATIONS
19	Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. <i>Blood</i> , 2011, 118, 4771-4779.	0.6	552
20	NF- κ B as a therapeutic target in cancer. <i>Trends in Molecular Medicine</i> , 2002, 8, 385-389.	3.5	544
21	Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade. <i>Clinical Cancer Research</i> , 2008, 14, 1649-1657.	3.2	532
22	A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance. <i>Cancer Cell</i> , 2012, 22, 345-358.	7.7	491
23	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.	0.6	438
24	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	0.6	436
25	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	5.1	394
26	American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2464-2472.	0.8	393
27	The role of the ubiquitin-proteasome pathway in apoptosis. <i>Cell Death and Differentiation</i> , 1999, 6, 303-313.	5.0	365
28	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
29	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1327-1337.	5.1	320
30	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 3777-3784.	0.6	306
31	The proteasome as a target for cancer therapy. <i>Clinical Cancer Research</i> , 2003, 9, 6316-25.	3.2	299
32	Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. <i>Blood</i> , 2005, 105, 3058-3065.	0.6	296
33	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	0.8	294
34	<i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5311-5321.	3.2	290
35	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
36	A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 7085-7091.	3.2	269

#	ARTICLE	IF	CITATIONS
37	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1311-1318.	5.1	239
38	An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. <i>Blood</i> , 2012, 119, 5661-5670.	0.6	235
39	Bortezomib in recurrent and/or refractory multiple myeloma. <i>Cancer</i> , 2005, 103, 1195-1200.	2.0	218
40	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 3307-3315.	3.2	203
41	Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. <i>Blood</i> , 2015, 126, 2284-2290.	0.6	201
42	Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. <i>Blood</i> , 2009, 113, 4667-4676.	0.6	194
43	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	0.6	178
44	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). <i>Blood</i> , 2014, 123, 78-85.	0.6	173
45	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	13.9	173
46	Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. <i>Blood</i> , 2012, 120, 3260-3270.	0.6	165
47	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.	0.8	161
48	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 34-43.	3.2	159
49	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	1.2	158
50	An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. <i>British Journal of Haematology</i> , 2012, 158, 739-748.	1.2	157
51	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2020, 21, 1317-1330.	5.1	155
52	ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. <i>Science Signaling</i> , 2016, 9, ra17.	1.6	147
53	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
54	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 1582-1596.	5.1	141

#	ARTICLE	IF	CITATIONS
55	A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2013, 161, 357-366.	1.2	138
56	A bis-Benzylidene Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer. <i>Cancer Cell</i> , 2013, 24, 791-805.	7.7	137
57	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). <i>Blood Cancer Journal</i> , 2020, 10, 53.	2.8	131
58	Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. <i>Blood</i> , 2017, 129, 1658-1668.	0.6	127
59	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. <i>Blood</i> , 2013, 122, 3122-3128.	0.6	126
60	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. <i>Blood</i> , 2014, 123, 4136-4142.	0.6	125
61	The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. <i>Breast Cancer Research</i> , 2002, 5, 1-7.	2.2	123
62	Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. <i>Oncotarget</i> , 2015, 6, 34329-34341.	0.8	123
63	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	3.2	122
64	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 42-49.	2.0	116
65	The BiTE (bispecific T cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.	2.0	116
66	Evidence of a Role for Activation of Wnt/ β -Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. <i>Journal of Biological Chemistry</i> , 2011, 286, 11009-11020.	1.6	114
67	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. <i>Cancer Cell</i> , 2017, 32, 88-100.e6.	7.7	114
68	Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 6469-6478.	3.2	112
69	Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. <i>Blood</i> , 2015, 126, 2475-2478.	0.6	108
70	An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 310-318.	0.2	104
71	Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis. <i>Journal of Biological Chemistry</i> , 2002, 277, 27864-27871.	1.6	100
72	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014, 123, 632-639.	0.6	98

#	ARTICLE	IF	CITATIONS
73	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.	2.8	90
74	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. <i>Cancer Cell</i> , 2016, 29, 639-652.	7.7	85
75	Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. <i>British Journal of Haematology</i> , 2009, 145, 481-490.	1.2	84
76	A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. <i>Blood</i> , 2014, 124, 2687-2697.	0.6	82
77	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e45-e54.	2.2	79
78	Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. <i>Clinical Cancer Research</i> , 2013, 19, 2248-2256.	3.2	78
79	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
80	Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥ 70 years with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 118-122.	0.6	74
81	Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. <i>British Journal of Haematology</i> , 2011, 152, 579-592.	1.2	69
82	Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	69
83	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. <i>Cancer</i> , 2008, 112, 1529-1537.	2.0	68
84	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e266-e275.	2.2	68
85	Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. <i>Blood</i> , 2015, 126, 505-505.	0.6	67
86	p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. <i>Cancer Research</i> , 2012, 72, 6393-6402.	0.4	66
87	Osteoblastic niche supports the growth of quiescent multiple myeloma cells. <i>Blood</i> , 2014, 123, 2204-2208.	0.6	66
88	Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. <i>Leukemia</i> , 2018, 32, 2224-2239.	3.3	66
89	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. <i>Blood Cancer Journal</i> , 2018, 8, 67.	2.8	66
90	Proteasome Inhibitors Induce a p38 Mitogen-activated Protein Kinase (MAPK)-dependent Anti-apoptotic Program Involving MAPK Phosphatase-1 and Akt in Models of Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 33-47.	1.1	64

#	ARTICLE	IF	CITATIONS
91	The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. <i>Journal of Biological Chemistry</i> , 2015, 290, 29854-29868.	1.6	64
92	Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik. <i>Molecular and Cellular Biology</i> , 2014, 34, 3435-3449.	1.1	63
93	Crystal-storing histiocytosis: a clinicopathological study of 13 cases. <i>Histopathology</i> , 2016, 68, 482-491.	1.6	60
94	Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. <i>British Journal of Haematology</i> , 2019, 186, e117-e121.	1.2	58
95	Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2014, 20, 1366-1374.	3.2	57
96	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. <i>Cell Metabolism</i> , 2021, 33, 78-93.e7.	7.2	57
97	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 352-355.	1.4	54
98	Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. <i>Annals of Hematology</i> , 2010, 89, 1133-1140.	0.8	54
99	Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer <i>In Vitro</i> and <i>In Vivo</i> via Exacerbating Unfolded Protein Responses. <i>Clinical Cancer Research</i> , 2014, 20, 3174-3186.	3.2	54
100	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. <i>Nature Communications</i> , 2015, 6, 8428.	5.8	53
101	Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. <i>Blood</i> , 2019, 133, 1572-1584.	0.6	53
102	CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies. <i>Cancer Research</i> , 2012, 72, 4225-4237.	0.4	51
103	RNA Polymerase I Inhibition with CX5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. <i>British Journal of Haematology</i> , 2017, 177, 80-94.	1.2	51
104	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	1.2	48
105	Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2243-2253.	1.9	47
106	Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. <i>British Journal of Haematology</i> , 2016, 172, 889-901.	1.2	47
107	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 522-530.e1.	0.2	47
108	Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. <i>Journal of Hematology and Oncology</i> , 2014, 7, 41.	6.9	46

#	ARTICLE	IF	CITATIONS
109	Effect of Long-term Storage in TRizol on Microarray-Based Gene Expression Profiling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2445-2452.	1.1	45
110	Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. <i>Blood</i> , 2015, 126, 25-25.	0.6	45
111	Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. <i>Annals of Hematology</i> , 2007, 86, 211-216.	0.8	43
112	A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 4617-4630.	2.0	43
113	Antigen-mediated regulation in monoclonal gammopathies and myeloma. <i>JCI Insight</i> , 2018, 3, .	2.3	43
114	Activating <i>KRAS</i> , <i>NRAS</i> , and <i>BRAF</i> mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20004-20014.	3.3	42
115	Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. <i>Clinical Cancer Research</i> , 2016, 22, 4901-4912.	3.2	41
116	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	2.0	40
117	Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. <i>Leukemia and Lymphoma</i> , 2016, 57, 1104-1113.	0.6	40
118	A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. <i>Cancer</i> , 2012, 118, 2507-2515.	2.0	39
119	Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S317-S329.	0.2	38
120	Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. <i>Seminars in Oncology</i> , 2013, 40, 634-651.	0.8	38
121	Chromosome 8q24.1/ <i>c-MYC</i> abnormality: a marker for high-risk myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 602-607.	0.6	38
122	HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. <i>Blood</i> , 2011, 118, 4140-4149.	0.6	36
123	Integration of Novel Agents into the Care of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5443-5452.	3.2	36
124	Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 110-114.	0.2	35
125	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34
126	New Drugs in Multiple Myeloma. <i>Annual Review of Medicine</i> , 2019, 70, 521-547.	5.0	34

#	ARTICLE	IF	CITATIONS
127	The Ubiquitin Proteasome Pathway from Bench to Bedside. Hematology American Society of Hematology Education Program, 2005, 2005, 220-225.	0.9	33
128	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica, 2015, 100, 100-106.	1.7	33
129	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Medicine, 2020, 17, e1003323.	3.9	33
130	Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage-Independent p53 Phosphorylation in Mantle Cell Lymphoma. Clinical Cancer Research, 2008, 14, 5416-5425.	3.2	30
131	Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma. Cancer Cell, 2013, 24, 275-277.	7.7	30
132	Future agents and treatment directions in multiple myeloma. Expert Review of Hematology, 2014, 7, 127-141.	1.0	30
133	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood, 2018, 132, LBA-2-LBA-2.	0.6	30
134	Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leukemia and Lymphoma, 2015, 56, 1335-1341.	0.6	29
135	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 687-693.	0.2	29
136	Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 472-476.	0.2	28
137	C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis. Science Signaling, 2017, 10, .	1.6	28
138	A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Advances, 2019, 3, 2400-2408.	2.5	28
139	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer, 2016, 122, 3831-3837.	2.0	27
140	Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM). Blood, 2012, 120, 1868-1868.	0.6	27
141	Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells. PLoS ONE, 2014, 9, e89064.	1.1	27
142	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2159-2164.	2.0	26
143	Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737. PLoS ONE, 2014, 9, e103015.	1.1	26
144	Anti-Ig2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget, 2015, 6, 8567-8578.	0.8	26

#	ARTICLE	IF	CITATIONS
145	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , 2012, 87, 272-276.	2.0	25
146	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018, 57, 529-538.	1.6	24
147	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	2.6	24
148	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 611-620.	1.2	23
149	A phase II trial of BAY 439006 (sorafenib) (NSC 724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. <i>Cancer Medicine</i> , 2014, 3, 1275-1283.	1.3	23
150	Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. <i>Cancer</i> , 2015, 121, 1138-1146.	2.0	23
151	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. <i>British Journal of Cancer</i> , 2018, 118, 388-397.	2.9	23
152	A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). <i>Blood</i> , 2019, 134, 3116-3116.	0.6	23
153	A sensitive procedure for determination of cathepsin D: activity in alveolar and peritoneal macrophages. <i>Molecular and Cellular Biochemistry</i> , 1984, 64, 155-62.	1.4	22
154	Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 625-631.	1.2	22
155	The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. <i>Neoplasia</i> , 2017, 19, 772-780.	2.3	22
156	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2197-2203.	2.0	22
157	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 227-237.	0.8	22
158	Targeting the proteasome as a therapeutic strategy against haematological malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 117-130.	1.9	21
159	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
160	Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. <i>Oncotarget</i> , 2017, 8, 59476-59491.	0.8	21
161	The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 381-392.	1.3	20
162	Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. <i>Bone Marrow Transplantation</i> , 2019, 54, 1089-1093.	1.3	20

#	ARTICLE	IF	CITATIONS
163	Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. <i>Oncotarget</i> , 2017, 8, 73723-73732.	0.8	20
164	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2015, 21, 2538-2545.	3.2	19
165	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1723-1726.	0.6	19
166	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	2.2	19
167	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1453-1458.	2.0	18
168	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1609-1618.	1.1	18
169	Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 977-985.	0.8	18
170	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study. <i>Blood</i> , 2009, 114, 2878-2878.	0.6	18
171	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. <i>J Clin Oncol</i> , 2016, 34, 90.		17
172	A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 80.	2.8	17
173	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 560-569.	0.2	17
174	Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis. <i>Blood</i> , 2015, 126, 4222-4222.	0.6	17
175	Novel Approaches to Treatment of Double-Refractory Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e302-e306.	1.8	17
176	Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. <i>Leukemia Research</i> , 2015, 39, 371-379.	0.4	16
177	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016, 91, E442-7.	2.0	16
178	Once-weekly (70 mg/m ²) vs twice-weekly (56 mg/m ²) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION trials. <i>Cancer Medicine</i> , 2020, 9, 2989-2996.	1.3	16
179	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. <i>Neoplasia</i> , 2021, 23, 361-374.	2.3	16
180	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	2.5	16

#	ARTICLE	IF	CITATIONS
181	Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. <i>International Journal of Cancer</i> , 2015, 136, 991-1002.	2.3	15
182	Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 74.	6.9	15
183	Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. <i>Lancet Haematology</i> , 2018, 5, e628-e640.	2.2	15
184	Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. <i>Clinical Cancer Research</i> , 2018, 24, 6408-6420.	3.2	15
185	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	0.6	15
186	Symptom burden and its functional impact in patients with asymptomatic relapsed or refractory multiple myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 467-475.	1.0	15
187	Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 424-432.	0.2	14
188	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018, 124, 2561-2569.	2.0	14
189	Proteasome Inhibitors in Cancer Therapy. , 2005, 301, 339-350.		13
190	Luteinizing Hormone-Releasing Hormone (LHRH)-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth <i>In vitro</i> and <i>In vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 148-158.	1.9	13
191	Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells. <i>Neoplasia</i> , 2015, 17, 289-300.	2.3	13
192	Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 3969-3978.	3.2	13
193	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021, 106, 3211-3214.	1.7	13
194	Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. <i>Neoplasia</i> , 2022, 24, 1-11.	2.3	12
195	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	2.0	11
196	Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. <i>European Journal of Haematology</i> , 2017, 99, 119-132.	1.1	11
197	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	0.6	11
198	Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 964-970.	0.6	11

#	ARTICLE	IF	CITATIONS
199	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	2.5	11
200	Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1982-1982.	0.6	11
201	Long-term outcomes for newly diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. <i>British Journal of Haematology</i> , 2015, 171, 373-377.	1.2	10
202	Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 459-473.	1.5	10
203	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	3.2	10
204	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , 2020, 105, e355-e357.	1.7	10
205	Bayesian Joint Selection of Genes and Pathways: Applications in Multiple Myeloma Genomics. <i>Cancer Informatics</i> , 2014, 13s2, CIN.S13787.	0.9	9
206	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. <i>European Journal of Haematology</i> , 2016, 97, 342-347.	1.1	9
207	Dose adjusted EPOCH and mediastinal disease may improve outcomes for patients with gray zone lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 503-506.	1.2	9
208	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e221-e238.	0.2	9
209	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301.	0.6	9
210	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 3155-3155.	0.6	9
211	Novel Approaches to Treatment of Double-Refractory Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e302-e306.	1.8	8
212	Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. <i>Leukemia Research</i> , 2014, 38, 896-900.	0.4	8
213	Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. <i>Annals of Hematology</i> , 2015, 94, 1605-1607.	0.8	8
214	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020, 16, e1169-e1180.	1.4	8
215	Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 1982-1982.	0.6	8
216	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	0.6	8

#	ARTICLE	IF	CITATIONS
217	Additional "structural" chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. <i>Modern Pathology</i> , 2017, 30, 843-853.	2.9	7
218	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e353-e354.	0.2	7
219	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e465-e469.	0.2	7
220	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. <i>Modern Pathology</i> , 2021, 34, 327-335.	2.9	7
221	Longer Term Follow up of the Å, Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). <i>Blood</i> , 2018, 132, 1992-1992.	0.6	7
222	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	1.3	7
223	Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. <i>Modern Pathology</i> , 2017, 30, 1378-1386.	2.9	6
224	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	1.1	6
225	Carfilzomib+dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1364-1374.	0.6	6
226	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	0.8	6
227	The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. <i>Journal of Molecular Medicine</i> , 2020, 98, 1161-1173.	1.7	6
228	Phase I/II study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2020, 105, e242-e245.	1.7	6
229	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1413-1417.	2.0	5
230	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.2	5
231	Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient. <i>Acta Haematologica</i> , 2018, 139, 67-70.	0.7	5
232	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	2.0	5
233	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 797-803.	0.2	5
234	Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 1816.	2.2	5

#	ARTICLE	IF	CITATIONS
235	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 11-18.	0.6	4
236	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 515-518.	0.6	4
237	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 94, E72-E74.	2.0	4
238	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1077-1083.	2.0	4
239	Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. <i>Clinical Cancer Research</i> , 2020, 26, 5814-5819.	3.2	4
240	Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma. <i>Blood</i> , 2005, 106, 1576-1576.	0.6	4
241	A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 1959-1959.	0.6	4
242	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 1277-1284.	3.2	4
243	Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. <i>Current Oncology</i> , 2022, 29, 2954-2972.	0.9	4
244	Letter-Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 487-487.	0.5	3
245	Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. <i>Blood Cancer Journal</i> , 2021, 11, 17.	2.8	3
246	Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. <i>British Journal of Haematology</i> , 2021, 193, e23-e26.	1.2	3
247	Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. <i>Supportive Care in Cancer</i> , 2021, 29, 6099-6107.	1.0	3
248	A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E243-E246.	2.0	3
249	Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2016, 128, 5628-5628.	0.6	3
250	SARS-CoV-2 in multiple myeloma: initial observation and management. <i>Leukemia and Lymphoma</i> , 2020, 61, 2763-2766.	0.6	2
251	Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. <i>Blood</i> , 2012, 120, 75-75.	0.6	2
252	Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial. <i>Blood</i> , 2015, 126, 875-875.	0.6	2

#	ARTICLE	IF	CITATIONS
253	Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E232-E235.	2.0	2
254	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	2
255	Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction Drugs. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S260-S261.	2.0	1
256	A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E319-E322.	2.0	1
257	Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. , 2021, 4, 888-902.		1
258	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 243.e1-243.e6.	0.6	1
259	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2011, 118, 333-333.	0.6	1
260	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. <i>Oncotarget</i> , 2017, 8, 41620-41630.	0.8	1
261	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 307.e1-307.e8.	0.6	1
262	Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2014, , 81-98.	0.1	0
263	Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. <i>Cancer Epidemiology</i> , 2021, 73, 101972.	0.8	0
264	A Systematic Review Evaluating the Addition of Radiation Therapy to Chemotherapy for Localized Aggressive Non-Hodgkin's Lymphoma: What Is the Role for Radiotherapy?.. <i>Blood</i> , 2004, 104, 3155-3155.	0.6	0
265	Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 113858-113873.	0.8	0
266	The future of proteasome inhibitors in relapsed/refractory multiple myeloma. <i>Oncology</i> , 2011, 25 Suppl 2, 56-64.	0.4	0
267	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. <i>American Journal of Cancer Research</i> , 2021, 11, 3285-3293.	1.4	0
268	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 264.e1-264.e9.	0.6	0